Entera Announces Third Quarter 2026 Financial Results and Business Updates

Entera Bio Ltd. (ENTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Entera Announces Third Quarter 2026 Financial Results and Business Updates Clinical Preparations Advanced for EB613 Phase 3 Osteoporosis Study, with First Site Activation Expected in Late 2026 Clinical and Commercial Leadership Expanded with Appointment of Senior Exe

Event · Earnings
Original reporting
Published Nov 6, 2026, 9:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 9:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$ENTX
Bullish
high confidence
Mentioned
$ENTX
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$ENTXBullishHigh
01

Why it matters

The filing introduces new Phase 2 efficacy data for EB613, outlines Phase 3 plans, and confirms a strong cash position, all of which are new and material for the stock.

02

Market read

First‑report of trial data and financials provides fresh catalyst for ENTX, likely influencing biotech sector sentiment.

03

What to watch

Potential regulatory delays and competition from established anabolic agents could temper upside.

Relevance 7/10Novelty 8/10Timing: after-hours filing
AlphAI · Earnings readENTX · Q3 2026 · ended 2026-09-30

Entera reports Q3 2026 net loss of $15.6 million, driven by a $7.5 million non-cash warrant remeasurement, as EB613 Phase 3 preparations advance and cash rose to $265.9 million after a $275.0 million private placement

→Mixed quarter

The company reported no revenue and a larger loss, with the company attributing the increase mainly to a $7.5 million non-cash warrant remeasurement and to Phase 3 start-up and OPKO collaboration activity. Balance sheet strength is substantial, with cash of $265.9 million and a company statement that cash is expected to fund the EB613 Phase 3 program through topline results and NDA submission and operations into 2030. The filing provides no revenue, no guidance and no prior-quarter comparison, so the read rests on clinical progress and the balance sheet.

Revenue
—

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Revenues, three months ended September 30, 2026GAAP—––
Research and development expenses, three months ended September 30, 2026GAAP$4,925 thousand ($4.9 million in text)–$3.3 million increase (as stated in text)
General and administrative expenses, three months ended September 30, 2026GAAP$2,340 thousand ($2.3 million in text)––
Total operating expenses, three months ended September 30, 2026GAAP$7.26M––
Operating loss, three months ended September 30, 2026GAAP$7.26M––
Financial expenses (income), net, three months ended September 30, 2026GAAP$8.33M––
Net loss, three months ended September 30, 2026GAAP$15,597 thousand ($15.6 million in text)––
Loss per ordinary share, basic and diluted, three months ended September 30, 2026GAAP$0.11––

What drove it

  • R&D expense rose to $4,925 thousand from $1,643 thousand. The company attributes the increase primarily to start-up activities for the EB613 Phase 3 program and to activities under the OPKO collaboration.
  • Company explanation for the higher net loss: a $7.5 million non-cash fair value remeasurement of pre-funded warrants issued in the April 2026 and July 2026 private placements, reclassified to equity in August 2026.
  • Financial expenses (income), net moved to $8,332 thousand of expense from $(56) thousand of income in the prior-year quarter. The filing does not break down this line beyond the warrant remeasurement described above.

Concerns

  • No revenue is reported in either period, so the net loss is entirely driven by operating expenses and the financial expense line.
  • The net loss more than quadrupled to $15,597 thousand from $3,200 thousand, and the financial expense line of $8,332 thousand is the largest contributor to the gap between operating loss and net loss.
  • The filing lists the Phase 3 topline readout in the second half of 2028 and the company's Nasdaq listing standards among forward-looking risk factors, which the company names as matters that could affect results.
  • The forward-looking statements section lists ability to continue as a going concern absent access to sources of liquidity as a risk factor, although the company states its cash is expected to fund operations into 2030.

What to watch

  • Timing of first clinical site activation for the EB613 Phase 3 study, which the company expects in late 2026.
  • Topline results from the EB613 Phase 3 study, anticipated in the second half of 2028.
  • Progress on the EB612 Phase 1 single ascending dose study, which the company plans to initiate in 2027.
  • Whether future quarters show a further change in financial expenses, net, following the August 2026 reclassification of the pre-funded warrants to equity.
  • Quarterly cash use against the $265.9 million cash balance, given the company's statement that cash supports operations into 2030.

Balance sheet and cash flow

  • Cash and cash equivalents: $265,883 thousand ($265.9 million) as of September 30, 2026, compared with $7,108 thousand as of December 31, 2025 (audited).
  • Restricted cash: $6,536 thousand ($6.5 million) as of September 30, 2026, primarily designated to fund the OPKO collaboration; $7,775 thousand as of December 31, 2025.
  • Total assets: $277,040 thousand as of September 30, 2026, compared with $15,993 thousand as of December 31, 2025.
  • Total liabilities: $2,758 thousand as of September 30, 2026, compared with $2,892 thousand as of December 31, 2025.
  • Total shareholders' equity: $274,282 thousand as of September 30, 2026, compared with $13,101 thousand as of December 31, 2025.
  • Private placement: in July 2026 the company completed an oversubscribed private placement with gross proceeds of approximately $275.0 million before placement agent fees and offering expenses, led by existing investor BVF Partners L.P.
  • Company statement: cash resources are expected to be sufficient to fully fund the planned Phase 3 registrational program of EB613 through topline results and the anticipated NDA submission, and to support operations into 2030.
  • Company statement: the net loss increase was primarily driven by a $7.5 million non-cash fair value remeasurement of pre-funded warrants issued in the April 2026 and July 2026 private placements, which were reclassified to equity in August 2026.

Analysis

Entera Bio reported no revenue for the quarter ended September 30, 2026, and a GAAP net loss of $15,597 thousand, or $0.11 per ordinary share, against a net loss of $3,200 thousand, or $0.07 per share, in the same quarter of 2025. Operating expenses rose to $7,265 thousand from $3,256 thousand. Research and development expense was $4,925 thousand against $1,643 thousand, and the company attributes the increase primarily to start-up activities for the EB613 Phase 3 program and to activities under the OPKO collaboration. General and administrative expense was $2,340 thousand against $1,613 thousand. The filing does not print a percentage change for either expense line.

Below operating loss, financial expenses (income), net moved to $8,332 thousand of expense from $(56) thousand of income. The company states that the net loss increase was primarily driven by a $7.5 million non-cash fair value remeasurement of pre-funded warrants issued in its April 2026 and July 2026 private placements, which were reclassified to equity in August 2026. The gap between the $7,265 thousand operating loss and the $15,597 thousand net loss is therefore largely this non-cash item, as the company describes it.

The balance sheet changed substantially. Cash and cash equivalents were $265,883 thousand at September 30, 2026, against $7,108 thousand at December 31, 2025, and restricted cash was $6,536 thousand, primarily designated to fund the OPKO collaboration. Total assets rose to $277,040 thousand from $15,993 thousand, and shareholders' equity to $274,282 thousand from $13,101 thousand. The increase follows the July 2026 private placement, which the company describes as oversubscribed with gross proceeds of approximately $275.0 million before placement agent fees and offering expenses. Total liabilities were $2,758 thousand. The company states that its cash is expected to fully fund the planned EB613 Phase 3 program through topline results and the anticipated NDA submission, and to support operations into 2030.

Operationally, the quarter centred on EB613 Phase 3 preparation. The company reported first clinical site activation expected in late 2026, a Phase 3 design of approximately 900 postmenopausal women randomized 2:1 to EB613 or placebo, and topline results anticipated in the second half of 2028. It also presented a post-hoc Phase 2 analysis at ASBMR 2026 in which bone turnover marker changes were enhanced in women with T-scores of -2.5 or lower. Two board appointments are effective December 1, 2026, and several senior clinical hires were announced. EB612 remains in IND-enabling work with OPKO, with a Phase 1 start planned for 2027.

The filing provides no guidance, no segment data, no cash flow statement and no prior-quarter comparison, so sequential trends cannot be read from the document. The primary figures to monitor are the operating expense run-rate as Phase 3 start-up activity scales, the non-cash financial expense line from the warrant accounting, and cash consumption against the reported balance.

Management, verbatim

The third quarter of 2026 transitioned our expanding team into late-stage clinical execution mode.

Miranda Toledano, Chief Executive Officer

Not in the filing

stated, not guessed
  • No revenue figure is printed beyond the dash shown for revenues, cost of revenues and gross profit; no revenue growth or gross margin can be stated.
  • No prior-year percentage change is printed for research and development, general and administrative, total operating expenses, operating loss, financial expenses, net loss or loss per share.
  • No prior-quarter (Q2 2026) figures are printed in the filing, so no quarter-over-quarter changes are available.
  • No consensus estimates or analyst expectations are in the documents.
  • No cash flow statement is included, so operating cash flow, investing cash flow and free cash flow are not reported.
  • No nine-month or year-to-date columns are printed.
  • No share repurchase or dividend activity is reported.
  • No segment or geographic revenue breakdown is provided.
  • The filing does not break down financial expenses (income), net beyond the warrant remeasurement the company describes as $7.5 million.
  • No share price reaction is included in the documents.
  • The previous outlook covered late 2026 through 2030 and gave no quarterly figures for Q3 2026 to compare with.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Background

Entera Bio Ltd. (NASDAQ: ENTX) released its third‑quarter 2026 financial results and business updates via an SEC Form 8‑K.

Company-level read

Ticker impact

$ENTXBullishHigh confidence
Context

Entera Bio filed its 8‑K reporting Q3 2026 results, new Phase 2 data for EB613 and leadership appointments.

Expected impact

likely upward pressure as investors price in encouraging trial data and ample cash balance

Evidence & confidence

The filing provides first‑report trial efficacy signals and a $265M cash position, both material for a small‑cap biotech.

Market effects

Strengthens the oral peptide biotech niche and may lift peer valuations.

Adds to Israeli‑based biotech activity, modest effect on US biotech sector.

Limited to biotech investors; no broad market impact.

Counterpoint

Trial data are post‑hoc and may not translate to Phase 3; investors could be over‑optimistic.

Key entities

  • Entera Bio Ltd.

    NASDAQ‑listed developer of oral peptide therapeutics.

  • EB613

    Oral anabolic peptide for osteoporosis, now entering Phase 3.

Every ENTX earnings report

This story covers one filing. The ticker page keeps them all: each quarter's reported metrics with year-over-year and sequential comparisons, segments, guidance, and how the numbers landed against the company's own prior outlook.

Related articles

$ENTXMedAI 8/10

A planned osteoporosis pill trial is expected to enroll about 900 women. Entera expects its first site to open in late 2026.

Entera Bio (ENTX) plans to initiate a Phase 3 trial for its osteoporosis drug EB613 in late 2026, with 900 women expected to enroll. The company presented Phase 2 data at ASBMR 2026, showing potential benefits for patients with low bone mineral density. Entera also announced key leadership appointments and financial results for Q3 2026.

$ENTXMedAI 8/10

Entera Bio to present Phase 3 trial design for oral osteoporosis drug

Entera Bio (ENTX) will present Phase 3 trial design for its oral osteoporosis drug, EB613, at a conference in October 2026. The study will evaluate EB613 in postmenopausal women with osteoporosis. The company previously reported positive Phase 2 results, showing improvements in bone density and markers. EB613 is an oral, once-daily tablet, unlike current anabolic therapies that require injections.

$ENTXMed

Entera Receives $9 Price Target and New 'Outperform' Rating From Leerink Partners (NASDAQ: ENTX)

Entera Bio (ENTX) received an 'Outperform' rating and $9 price target from Leerink Partners. The company's lead drug, EB613, is in development for osteoporosis and has completed Phase 2 trials. Entera recently raised $275M in funding and plans to initiate Phase 3 trials in late 2026, with data expected in 2028. ENTX was trading at $3.03 per share as of September 17, 2026.

$ENTXMedAI 8/10

Entera Bio Q2 EPS misses estimate as net loss widens to $7.3 million

Entera Bio Ltd. (NASDAQ: ENTX) reported Q2 2026 EPS loss of $0.14 versus a $0.08 consensus estimate, with net loss widening to $7.3 million from $2.7 million a year earlier, driven mainly by a $2.7 million non-cash warrant fair value remeasurement. The company also closed an oversubscribed $275 million private placement to fund EB613 Phase 3 NDA work through 2030.